(CercleFinance.com) – GSK announced Friday evening that the US Food and Drug Administration (FDA) had approved Ojjaara for the treatment of myelofibrosis associated with anemia, becoming the first and only drug expressly authorized in this of this indication.
Myelofibrosis, a brain cancer that affects about 25,000 people in the United States, leads in most cases to anemia, forcing patients to stop treatment and undergo blood transfusions.
GSK got its hands on momelotinib, Ojjaara’s scientific name, last year as part of its $1.9 billion takeover of Californian biotech Sierra Oncology.
The British laboratory then declared that it expected the drug to generate sales from the 2023 financial year, before generating ‘significant’ growth thereafter.
Ojjaara is not currently authorized in any other country, GSK specifies in its press release.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
This is a Smartvoice article: see legal notices